Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 12/20 | 1.00 |
| ▸ | KDR | P35968 | 10/20 | 1.00 |
| ▸ | PIK3CD | O00329 | 6/20 | 0.64 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.64 |
| ▸ | PIK3CB | P42338 | 4/20 | 0.64 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.64 |
| ▸ | PRKDC | P78527 | 4/20 | 0.64 |
| ▸ | SRC | P12931 | 5/20 | 0.62 |
| ▸ | ABL1 | P00519 | 4/20 | 0.62 |
| ▸ | EGFR | P00533 | 4/20 | 0.62 |
| ▸ | HCK | P08631 | 3/20 | 0.62 |
| ▸ | MTOR | P42345 | 3/20 | 0.62 |
| ▸ | EPHB4 | P54760 | 3/20 | 0.62 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.60 |
| ▸ | BTK | Q06187 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19463767 | 1.00 | RET (1.00) | RETKDRPIK3CDPIK3CAPIK3CB | |
| SCHEMBL6940447 | 0.97 | RET (0.94) | RETKDRPIK3CDPIK3CAPIK3CB | |
| SCHEMBL19492187 | 0.91 | RET (0.83) | RETKDRPIK3CDPIK3CAPIK3CB | |
| SCHEMBL16655548 | 0.88 | RET (0.78) | RETKDRPIK3CDSRCABL1 | |
| SCHEMBL12422336 | 0.87 | PIK3CD (0.82) | RETKDRPIK3CDPIK3CAPIK3CB | |
| SCHEMBL19463360 | 0.87 | RET (1.00) | RETKDRPIK3CDSRCABL1 | |
| SCHEMBL30455306 | 0.86 | RET (1.00) | RETKDRPIK3CDPIK3CAPIK3CB | |
| SCHEMBL12422304 | 0.86 | PIK3CD (0.84) | RETKDRPIK3CDPIK3CAPIK3CB | |
| SCHEMBL19492101 | 0.86 | RET (1.00) | RETKDRPIK3CDPIK3CAPIK3CB | |
| SCHEMBL19492253 | 0.86 | RET (1.00) | RETKDRPIK3CDPIK3CAPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240116938-A1 | Heterocyclic Compounds as RET Kinase Inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2024-04-11 | — | — | US | disclosed |
| US-11661423-B2 | Heterocyclic compounds as RET kinase inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11661423-B2 | Heterocyclic compounds as RET kinase inhibitors | RET, HIPK4, HIPK3 | RET 1/4885KDR 793/4885PIK3CD 372/4885 |
| US-20240116938-A1 | Heterocyclic Compounds as RET Kinase Inhibitors | RET, HIPK4, HIPK3 | RET 1/4885KDR 793/4885PIK3CD 372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.